Application of antibody-drug conjugates in colorectal cancer

Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide, and metastatic disease responds poorly to conventional surgery, chemotherapy, and targeted therapy. Antibody-drug conjugates (ADCs) link monoclonal antibodies to cytotoxic payloads through chemical linkers, enabling antigen-specific delivery, intracellular payload release, bystander killing, and Fc-mediated immune effects. ADC efficacy and safety depend on target antigen selection, antibody design, payload choice, linker stability, and internalization efficiency. This narrative review, based on literature and trial data available up to February 2026, summarizes the CRC treatment landscape, ADC mechanisms and component optimization, and clinical progress of ADCs targeting HER2, HER3, TROP-2, CEACAM5, and c-MET. No ADC has been approved specifically for CRC; trastuzumab deruxtecan has tumor-agnostic accelerated approval for HER2 IHC 3+ solid tumors and may cover eligible patients with metastatic CRC. Early trials show promising activity but substantial hematologic, gastrointestinal, hepatic, and interstitial lung disease toxicity, reflecting a narrow therapeutic window. We discuss challenges including target specificity, off-target toxicity, drug resistance, and linker stability, and outline future directions such as probody-drug conjugates, bispecific and dual-payload ADCs, novel payloads, and bioorthogonal linkers to support precision therapy for CRC.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-13
DOI
https://doi.org/10.3389/fonc.2026.2011302
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Application of antibody-drug conjugates in colorectal cancer

JingZhe Li, Pan Huang, Qiang Cai, Huazhong Cai et al.
6 links
Frontiers in Oncology
Colorectal Cancer Treatments and Studies
article

Application of antibody-drug conjugates in colorectal cancer

JingZhe Li, Pan Huang, Qiang Cai, Huazhong Cai, Ying Liu
article en

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide, and metastatic disease responds poorly to conventional surgery, chemotherapy, and targeted therapy. Antibody-drug conjugates (ADCs) link monoclonal antibodies to cytotoxic payloads through chemical linkers, enabling antigen-specific delivery, intracellular payload release, bystander killing, and Fc-mediated immune effects. ADC efficacy and safety depend on target antigen selection, antibody design, payload choice, linker stability, and internalization efficiency. This narrative review, based on literature and trial data available up to February 2026, summarizes the CRC treatment landscape, ADC mechanisms and component optimization, and clinical progress of ADCs targeting HER2, HER3, TROP-2, CEACAM5, and c-MET. No ADC has been approved specifically for CRC; trastuzumab deruxtecan has tumor-agnostic accelerated approval for HER2 IHC 3+ solid tumors and may cover eligible patients with metastatic CRC. Early trials show promising activity but substantial hematologic, gastrointestinal, hepatic, and interstitial lung disease toxicity, reflecting a narrow therapeutic window. We discuss challenges including target specificity, off-target toxicity, drug resistance, and linker stability, and outline future directions such as probody-drug conjugates, bispecific and dual-payload ADCs, novel payloads, and bioorthogonal linkers to support precision therapy for CRC.

Frontiers in OncologyVol. 16
Jiangsu University (CN), Southeast University (BD), Affiliated Hospital of Jiangsu University (CN), Southeast University (CN)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon